Your browser doesn't support javascript.
loading
Target Deconvolution Efforts on Wnt Pathway Screen Reveal Dual Modulation of Oxidative Phosphorylation and SERCA2.
Casás-Selves, Matias; Zhang, Andrew X; Dowling, James E; Hallén, Stefan; Kawatkar, Aarti; Pace, Nicholas J; Denz, Christopher R; Pontz, Timothy; Garahdaghi, Farzin; Cao, Qing; Sabirsh, Alan; Thakur, Kumar; O'Connell, Nichole; Hu, Jun; Cornella-Taracido, Iván; Weerapana, Eranthie; Zinda, Michael; Goodnow, Robert A; Castaldi, M Paola.
Affiliation
  • Casás-Selves M; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Zhang AX; Present address: Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Suite 510, Toronto, ON, M5G 0A3, Canada.
  • Dowling JE; Discovery Sciences-Chemical Biology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Hallén S; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Kawatkar A; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Discovery Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden.
  • Pace NJ; Discovery Sciences-Chemical Biology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Denz CR; Department of Chemistry, Boston College, Chestnut Hill, MA, 02467, USA.
  • Pontz T; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Garahdaghi F; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Cao Q; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Sabirsh A; Present address: Synageva BioPharma Corp., 33 Hayden Avenue, Lexington, MA, 02421, USA.
  • Thakur K; Discovery Sciences-Computational Chemistry, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • O'Connell N; Present address: Ra Pharmaceuticals, Inc., 87 Cambridge Park Drive, Cambridge, MA, 02140, USA.
  • Hu J; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Discovery Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden.
  • Cornella-Taracido I; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Weerapana E; Discovery Sciences-Structure and Biophysics, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Zinda M; Present address: Nurix, Inc., 1700 Owens Street, Suite 290, San Francisco, CA, 94158, USA.
  • Goodnow RA; Discovery Sciences-Structure and Biophysics, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.
  • Castaldi MP; Present address: Shire, 300 Shire Way, Lexington, MA, 02421, USA.
ChemMedChem ; 12(12): 917-924, 2017 06 21.
Article in En | MEDLINE | ID: mdl-28371485
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oxidative Phosphorylation / Thiadiazoles / Sarcoplasmic Reticulum Calcium-Transporting ATPases / Wnt Signaling Pathway Limits: Humans Language: En Year: 2017 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oxidative Phosphorylation / Thiadiazoles / Sarcoplasmic Reticulum Calcium-Transporting ATPases / Wnt Signaling Pathway Limits: Humans Language: En Year: 2017 Type: Article